In addition, an in vivo study in mice with ovarian cancer, the APOA1 peptide, L-5F, repressed tumor angiogenesis by inhibiting the vascular endothelial growth factor (VEGF) and basic fibroblast growth factor (bFGF) signaling pathways [202], indicating the use of L-5F as a candidate therapeutic strategy to reduce the size and number of tumor blood vessels. Here, APOA1 is linked to ovarian carcinoma.